BioTAK Blood Test for Broken Heart Syndrome
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 21, 2026
The BioTAK score points to a growing market for non-invasive cardiac diagnostics, potentially reducing demand for some catheterization lab procedures while expanding the use of specialized blood biomarker testing. Commercialization remains years away pending outcome trials, so near-term impact on device makers, hospital operators and diagnostics companies is limited but directionally supportive of the less-invasive cardiac assessment trend.
An international research team led by scientists at the University of Zurich and University Medical Center Greifswald developed and validated the BioTAK score, a blood-based diagnostic tool that distinguishes Takotsubo syndrome, commonly known as broken heart syndrome, from a genuine heart attack. Takotsubo syndrome is a sudden weakening of the heart muscle usually triggered by intense emotional or physical stress, and it most often affects postmenopausal women. It accounts for roughly 2 percent of patients initially thought to be having a heart attack, rising to as many as one in ten women presenting with acute coronary syndrome. Because symptoms, electrocardiogram changes and elevated cardiac enzymes overlap almost completely with a heart attack, patients currently must undergo invasive cardiac catheterization to rule out blocked coronary arteries. The BioTAK score combines biological sex with several blood biomarkers, including NT-proBNP, PAM, sLOX-1 and LDL cholesterol, selected using artificial intelligence. In an independent validation group of nearly 1,800 patients, the score correctly classified close to 90 percent of participants before catheterization. Two of the biomarkers point toward the brain-heart axis, suggesting Takotsubo syndrome develops through mechanisms independent of atherosclerosis. The study, published in the European Heart Journal, drew on more than 3,600 patients from the Swiss SPUM-ACS Registry and the International Takotsubo (InterTAK) Registry. Researchers including Florian A. Wenzl, Victor Schweiger, Thomas Lüscher and Christian Templin stressed that the score is not a substitute for cardiac catheterization when medically necessary, and that further trials are needed to determine whether it improves patient outcomes in routine care.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard